|
SLBP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.7554000031339E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.48889999721058E-08 |
| Normal-vs-Stage2 |
2.015200E-01 |
| Normal-vs-Stage3 |
3.14670000001183E-06 |
| Normal-vs-Stage4 |
1.50210000005035E-06 |
| Stage1-vs-Stage2 |
1.783630E-02 |
| Stage1-vs-Stage3 |
8.895000E-01 |
| Stage1-vs-Stage4 |
4.782400E-01 |
| Stage2-vs-Stage3 |
3.941800E-02 |
| Stage2-vs-Stage4 |
1.395570E-02 |
| Stage3-vs-Stage4 |
4.394000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.34550000532963E-08 |
| Normal-vs-AfricanAmerican |
1.364970E-03 |
| Normal-vs-Asian |
3.05929999999677E-06 |
| Caucasian-vs-AfricanAmerican |
3.489800E-01 |
| Caucasian-vs-Asian |
6.112000E-01 |
| AfricanAmerican-vs-Asian |
5.955200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.16909999967352E-07 |
| Normal-vs-Female |
9.94140000321053E-08 |
| Male-vs-Female |
3.728800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.23819999703545E-08 |
| Normal-vs-Age(41-60Yrs) |
3.18980000002522E-06 |
| Normal-vs-Age(61-80Yrs) |
3.759800E-04 |
| Normal-vs-Age(81-100Yrs) |
3.199300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.365200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.795770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.129200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.230200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.257600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.349200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.656600E-01 |
| Classical-VS-Follicular |
1.157950E-04 |
| Classical-VS-Other |
9.636600E-01 |
| Classical-VS-Normal |
2.71429989595617E-10 |
| Tall-VS-Follicular |
4.395400E-03 |
| Tall-VS-Other |
7.707200E-01 |
| Tall-VS-Normal |
1.20189999996967E-06 |
| Follicular-VS-Other |
2.084400E-01 |
| Follicular-VS-Normal |
1.878250E-01 |
| Other-VS-Normal |
1.241800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.04690000000074E-05 |
| Normal-vs-N1 |
1.219320E-03 |
| N0-vs-N1 |
8.496000E-01 |
|
|
